[Treatment of growth hormone deficiencies with growth hormone releasing hormone. Current status and perspectives].
Results of clinical trials performed with human hypothalamic growth hormone releasing factor (GRF) are conflicting, but rather disappointing for most of them. Pulsatile administration of GRF has been found to increase growth hormone secretion as well as growth velocity, but is not convenient for practical use. All other routes and rhythms of administration lead only to sub-optimal results, and generally does not seem to procure an appropriate GRF bio-availability. Improvements are possible, particularly the development of agonists and new galenic forms with sustained release. Therapeutic approach with hexapeptides, or hexapeptides analogs, looks promising, but could be more complementary than competitive.
Auzerie
J
J
Centre d'exploration endocrinologique, Bordeaux, France.
Colle
M
M
Guinot
P
P
Lavergne
V
V
D002648:Child; D004333:Drug Administration Routes; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000172:deficiency*; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans
D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone
Traitement des déficits en hormone de croissance par le facteur hypothalamique de libération de l'hormone de croissance. Etat actuel et perspectives.